[PDF][PDF] SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications

V Quagliariello, A Bonelli, A Caronna… - Eur. Rev. Med …, 2020 - europeanreview.org
NLRP3 (NOD-, LRR-and pyrin domain-containing protein 3) inflammasome has recently
become an intriguing target of several chronic and viral diseases. Here, we argue that …

The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies

N Zhao, B Di, L Xu - Cytokine & growth factor reviews, 2021 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), exhibits a wide spectrum of clinical presentations …

Targeting the NLRP3 inflammasome in severe COVID-19

TL Freeman, TH Swartz - Frontiers in immunology, 2020 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the genus
Betacoronavirus within the family Coronaviridae. It is an enveloped single-stranded positive …

Targeting of the NLRP3 Inflammasome for Early COVID-19

C Marchetti, K Mould, IW Tengesdal, WJ Janssen… - bioRxiv, 2021 - biorxiv.org
Following entry and replication of Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-
CoV-2) into ACE2 expressing cells, the infected cells undergo lysis releasing more virus but …

Novel coronavirus-induced NLRP3 inflammasome activation: a potential drug target in the treatment of COVID-19

A Shah - Frontiers in immunology, 2020 - frontiersin.org
Novel coronaviruses (nCoVs) encode ion-channel proteins called viroporins such as protein
E, open reading frame 3a (ORF3a) and ORF8a. These viroporins, via mechanisms such as …

Investigating the Nexus of NLRP3 Inflammasomes and COVID-19 Pathogenesis: Unraveling Molecular Triggers and Therapeutic Strategies

Q He, D Hu, F Zheng, W Chen, K Hu, J Liu, C Yao, H Li… - Viruses, 2024 - mdpi.com
The coronavirus disease 2019 (COVID-19) global pandemic, caused by severe acute
respiratory syndrome coronavirus type 2 (SARS-CoV-2), has been marked by severe cases …

NLRP3, the inflammasome and COVID-19 infection

M Yin, L Marrone, CG Peace… - QJM: An International …, 2023 - academic.oup.com
Abstract Severe coronavirus disease 2019 (COVID-19) is characterized by respiratory
failure, shock or multiorgan dysfunction, often accompanied by systemic hyperinflammation …

Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications

N Potere, MG Del Buono, R Caricchio, PC Cremer… - …, 2022 - thelancet.com
A hyperinflammatory response during severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus disease 2019 …

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

I Madurka, A Vishnevsky, JB Soriano, SJ Gans… - Infection, 2023 - Springer
Background Coronavirus-associated acute respiratory distress syndrome (CARDS) has
limited effective therapy to date. NLRP3 inflammasome activation induced by SARS-CoV-2 …

[HTML][HTML] NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity

S Amin, S Aktar, MM Rahman, MMH Chowdhury - Microbes and infection, 2022 - Elsevier
NLRP3 inflammasome is a critical immune component that plays a crucial role in mounting
innate immune responses. The deleterious effects of inflammasome activation have been …